Acknowledgement
Supported by : National Research Foundation of Korea (NRF), Ministry of Health & Welfare
References
- Falsey, A. R. and E. E. Walsh. 2005. Respiratory syncytial virus infection in elderly adults. Drugs Aging 22: 577-587. https://doi.org/10.2165/00002512-200522070-00004
- Murphy, B. R. and E. E. Walsh. 1988. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26: 1595-1597.
- Connors, M., N. A. Giese, A. B. Kulkarni, C. Y. Firestone, H. C. 3rd Morse, and B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68: 5321-5325.
- Kim, H. W., S. L. Leikin, J. Arrobio, C. D. Brandt, R. M. Chanock, and R. H. Parrott. 1976. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr. Res. 10: 75-78. https://doi.org/10.1203/00006450-197601000-00015
- Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson. 1996. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70:2852-2860.
- Collins, P. L., R. H. Purcell, W. T. London, L. A. Lawrence, R. M. Chanock, and B. R. Murphy. 1990. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8: 164-168. https://doi.org/10.1016/0264-410X(90)90141-8
- Jang, J. E., J. B. Lee, K. H. Kim, S. M. Park, B. S. Shim, I. S. Cheon, M. K. Song, and J. Chang. 2011. Evaluation of protective efficacy of respiratory syncytial virus vaccine against A and B subgroup human isolates in Korea. PLoS ONE 6: e23797. https://doi.org/10.1371/journal.pone.0023797
- Yu, J. R., S. Kim, J. B. Lee, and J. Chang. 2008. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol. 82: 2350-2357. https://doi.org/10.1128/JVI.02372-07
- Dormitzer, P. R., G. Galli, F. Castellino, H. Golding, S. Khurana, G. Del Giudice, and R. Rappuoli. 2011. Influenza vaccine immunology. Immunol. Rev. 239: 167-177. https://doi.org/10.1111/j.1600-065X.2010.00974.x
- Kim, S., D. H. Joo, J. B. Lee, B. S. Shim, I. S. Cheon, J. E. Jang, H. H. Song, K. H. Kim, M. K. Song, and J. Chang. 2012. Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant. PLoS One 7: e32226. https://doi.org/10.1371/journal.pone.0032226
- Lee, J. B., J. E. Jang, M. K. Song, and J. Chang. 2009. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS One 4: e5190. https://doi.org/10.1371/journal.pone.0005190
- Kim, S. and J. Chang. 2012. Baculovirus-based vaccine displaying respiratory syncytial virus glycoprotein induces protective immunity against RSV infection without vaccine- enhanced disease. Immune Netw. 12: 8-17. https://doi.org/10.4110/in.2012.12.1.8
- Bembridge, G. P., N. Rodriguez, R. Garcia-Beato, C. Nicolson, J. A. Melero, and G. Taylor. 2000. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19: 1038-1046. https://doi.org/10.1016/S0264-410X(00)00344-3
- Tripp, R. A., L. P. Jones, L. M. Haynes, H. Zheng, P. M. Murphy, and L. J. Anderson. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2: 732-738. https://doi.org/10.1038/90675
- Plotnicky-Gilquin, H., L. Goetsch, T. Huss, T. Champion, A. Beck, J. F. Haeuw, T. N. Nguyen, J. Y. Bonnefoy, N. Corvaïa, and U. F. Power. 1999. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J. Virol. 73: 5637-5645.
- Caton, A. J., G. G. Brownlee, J. W. Yewdell, and W. Gerhard. 1982. The antigenic structure of the influenza virusA/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417-427. https://doi.org/10.1016/0092-8674(82)90135-0
- Khurana, S., C. Larkin, S. Verma, M. B. Joshi, J. Fontana, A. C. Steven, L. R. King, J. Manischewitz, W. McCormick, R. K. Gupta, and H. Golding. 2011. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 29: 5657-5665. https://doi.org/10.1016/j.vaccine.2011.06.014
- Song, L., V. Nakaar, U. Kavita, A. Price, J. Huleatt, J. Tang, A. Jacobs, G. Liu, Y. Huang, P. Desai, G. Maksymiuk, V. Takahashi, S. Umlauf, L. Reiserova, R. Bell, H. Li, Y. Zhang, W. F. McDonald, T. J. Powell, and L. Tussey. 2008. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 3: e2257. https://doi.org/10.1371/journal.pone.0002257
Cited by
- Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses vol.10, pp.5, 2012, https://doi.org/10.4161/hv.28407
- The Next Generation of Influenza Vaccines: Towards a Universal Solution vol.9, pp.1, 2012, https://doi.org/10.3390/vaccines9010026